Selective Serotonin Reuptake Inhibitors (Ssri)

Life-threatening serotonin syndrome reported during combined use with almotriptan.

Concomitant use may result in serotonin syndrome. Patient requires careful observation, particularly during initiation and dose adjustment.

Co-administration with bivalirudin associated with increased risk of major bleeding events in patients undergoing PCI/PTCA.

Concomitant use may increase the risk of bleeding. Avoid concomitant use when possible and monitor closely for bleeding.

SSRIs affect platelet activation and concomitant use with clopidogrel may increase the risk of bleeding.

Increases risk of bleeding when coadministered with clopidogrel.

Postmarketing cases of serotonin syndrome reported during combined use. Careful observation advised, particularly during treatment initiation or dose increases.

Concomitant use increases risk of serotonin syndrome. Use with lower doses and monitor for serotonin syndrome symptoms.

Concomitant use increases the risk of serotonin syndrome. Monitor for signs and symptoms, particularly during initiation or dosage increase.

Concomitant use increases risk of serotonin syndrome. Initiate with lower doses and monitor for signs and symptoms.

SSRIs with diclofenac potentiate risk of bleeding more than NSAID alone due to serotonin reuptake interference.

SSRIs with diclofenac potentiate bleeding risk more than NSAID alone. Monitor for signs of bleeding.

Concomitant use potentiates bleeding risk more than NSAID alone. Monitor for signs of bleeding.

Concomitant use potentiates bleeding risk more than NSAID alone due to effects on serotonin reuptake and platelet hemostasis.

Concomitant use may potentiate risk of bleeding more than NSAID alone due to serotonin reuptake interference.

Coadministration increases the risk of bleeding.

Concomitant use with other SSRIs is not recommended; risk of serotonin syndrome.

Concomitant use increases risk of serotonin syndrome. Monitor for signs and symptoms.

Concomitant use may result in serotonin syndrome including altered mental status, autonomic instability, and neuromuscular symptoms.

Concomitant use may result in serotonin syndrome. Frequently evaluate patient during treatment initiation and dose adjustment.

SSRIs with ibuprofen potentiate bleeding risk more than NSAID alone due to interference with serotonin reuptake.

Concomitant use with SSRIs and NSAIDs potentiates the risk of bleeding more than NSAID alone.

Concomitant use has resulted in serotonin syndrome.

Concomitant administration can precipitate serotonin syndrome. Monitor for signs and symptoms, particularly during lithium initiation.

Concomitant use potentiates risk of bleeding more than NSAID alone due to serotonin reuptake interference affecting platelet hemostasis.

Concomitant use may result in serotonin syndrome. Carefully observe patient during treatment initiation and dosage modification; discontinue metaxalone if serotonin syndrome occurs.

Concomitant use may result in serotonin syndrome with serious CNS reactions, potentially fatal.

Concomitant use can result in serotonin syndrome. Requires frequent patient evaluation, particularly during initiation and dose adjustment.

Concomitant use may result in serotonin syndrome. Carefully observe patient during treatment initiation and dose adjustment.

SSRIs with naproxen potentiate risk of bleeding more than NSAID alone due to interference with serotonin reuptake and platelet hemostasis.

Concomitant use with naproxen potentiates bleeding risk more than NSAID alone by interfering with serotonin reuptake important for hemostasis.

Concomitant use potentiates bleeding risk more than NSAID alone due to serotonin reuptake interference.

Concomitant use may cause serotonin syndrome including altered mental status, autonomic instability, and neuromuscular symptoms. Monitor for emergence of serotonin syndrome.

Concomitant use may cause serotonin syndrome including altered mental status, autonomic instability, and neuromuscular symptoms. Monitor for emergence of serotonin syndrome; discontinue ondansetron if symptoms occur.

Concomitant use with serotonergic drugs has resulted in serotonin syndrome.

Concomitant use may cause serotonin syndrome including altered mental status, autonomic instability, and neuromuscular symptoms. Monitor for symptoms and discontinue palonosetron if they occur.

Concomitant use may cause serotonin syndrome including altered mental status, autonomic instability, and neuromuscular symptoms. Monitor for emergence and discontinue palonosetron if symptoms occur.

Concomitant use may potentiate bleeding risk more than NSAID alone by impairing platelet serotonin function.

Concomitant use may result in serotonin syndrome.

SSRIs co-administered with rizatriptan have been reported to cause serotonin syndrome.

SSRIs co-administered with rizatriptan may cause serotonin syndrome.

Severe toxicity reported in patients receiving combination of selective serotonin reuptake inhibitors and selegiline hydrochloride.

Cases of serotonin syndrome reported during coadministration of sumatriptan and SSRIs. Monitor for serotonin syndrome symptoms.

Cases of life-threatening serotonin syndrome have been reported during combined use of SSRIs and triptans.

Concomitant use may result in serotonin syndrome. Frequent patient evaluation is recommended during initiation and dose adjustment.

Concomitant use increases risk of serotonin syndrome. Monitor patients for signs and symptoms during trazodone initiation.

Potential for serotonin syndrome when coadministered. Careful patient observation advised, particularly during treatment initiation and dose increases.

SSRIs concomitantly used with zolmitriptan have caused life-threatening serotonin syndrome.

Concomitant use may result in serotonin syndrome; monitor regularly during initiation and dose adjustment.

Concomitant use potentiates bleeding risk more than NSAID alone by affecting platelet serotonin release. Monitor for signs of bleeding.

Use of FRAGMIN with thrombolytic agents may increase the risk of bleeding.

Concomitant use may increase risk of water intoxication with hyponatremia; requires more frequent serum sodium monitoring.

May increase risk of water intoxication with hyponatremia. Monitor serum sodium more frequently.

Concomitant use may increase risk of hyponatremia through SIADH. Avoid use; if unavoidable, closely monitor serum sodium concentrations.

Monitor for signs of bleeding with concomitant use of diclofenac and SSRIs due to increased bleeding risk.

SSRIs with diclofenac may potentiate bleeding risk more than NSAID alone due to effects on platelet serotonin reuptake.

Concomitant use may potentiate risk of bleeding more than NSAID alone; monitor for signs of bleeding.

Concomitant use may cause serotonin syndrome including altered mental status, autonomic instability, and neuromuscular symptoms. Monitor for emergence of serotonin syndrome.

Antidepressants that inhibit norepinephrine transporter function, causing potential false negative imaging results. Discontinue for at least 5 biological half-lives before administration.

CAPLYTA's moderate SERT activity may increase risk of SRI-associated adverse reactions including serotonin syndrome and hyponatremia. Increased monitoring recommended.

Concomitant use may potentiate bleeding risk more than NSAID alone; monitor for signs of bleeding.

Methylphenidate may inhibit metabolism of SSRIs. Downward dose adjustments may be required and plasma concentrations should be monitored.

Methylphenidate may inhibit metabolism of SSRIs; downward dose adjustment may be required and plasma concentrations should be monitored.

Levels may be increased in CYP2D6-deficient individuals due to modafinil's CYP2C19 inhibition affecting ancillary elimination routes. Dose adjustment may be necessary.

Bupropion inhibits CYP2D6 and can increase SSRI concentrations. Consider dose reduction when using with CONTRAVE.

Concomitant use may potentiate bleeding risk more than naproxen alone due to serotonin reuptake interference.

Serotonergic drugs may cause serotonin syndrome; careful observation required during treatment initiation and dose adjustment.

Risk of serotonin syndrome due to additive serotonergic effects; careful observation required during treatment initiation and dose increases.

Safety and effectiveness of concomitant use with argatroban have not been established.